Afatinib Tablets 30 Mg – Generic Gilotrif

What is Afatinib 30 Mg?

Afatinib Tablets 30 mg is a targeted cancer therapy used primarily in the treatment of metastatic non-small cell lung cancer (NSCLC), especially in patients diagnosed with mutations in the epidermal growth factor receptor (EGFR) gene. The drug is classified as a tyrosine kinase inhibitor (TKI) that works by irreversibly blocking cancer-causing signals in mutated EGFR proteins.

This medication is the generic version of Gilotrif, the American brand name of Afatinib approved by the FDA. It offers the same therapeutic quality and effectiveness for EGFR-positive patients, typically at a more affordable price point.

Key Features and Benefits

• Generic equivalent of Gilotrif (USA brand)
• FDA-approved EGFR TKI for NSCLC treatment
• Improved pricing, same clinical results
• Safely used in dose-reduction from standard 40 mg
• Irreversible EGFR blockade – improved disease control
• Oral once-daily tablet for easy administration
• Extends progression-free survival vs. chemotherapy

How Afatinib (Generic Gilotrif) Works

Afatinib, like its branded counterpart Gilotrif, blocks the growth signals in cancer cells by inactivating the EGFR, a protein responsible for stimulating growth in tumor cells. In certain EGFR-mutated lung cancers, excessive signaling leads to uncontrolled growth. By irreversibly binding to this receptor, Afatinib prevents further cell division and metastasis.

The 30 mg dose is suitable for patients who:

• Require dosage reduction due to side effects from the 40 mg standard dose
• Begin therapy more conservatively under physician discretion
• Have shown prior intolerance to full-dose therapy

Clinical Indications

Afatinib 30 mg (Generic Gilotrif) is indicated in the treatment of:

• Metastatic NSCLC with EGFR exon 19 deletions or exon 21 substitutions (L858R)
• Patients who have developed side effects (e.g., diarrhea, rash) requiring dose adjustments
• Those who previously responded to first-generation TKIs but require a second-generation inhibitor

Dosage and Administration

• Recommended starting dose: 40 mg once daily
• Reduced dose (Afatinib 30 mg) is used if patients experience side effects
• Administration: Take once daily on an empty stomach (at least 1 hour before or 2 hours after meals)
• Swallow whole with water; do not split, chew, or crush

Always take Afatinib under the supervision of a qualified oncologist. Treatment should continue as prescribed or until disease progression or intolerable side effects occur.

Dose-optimized targeted therapy programs may incorporate Axitinib Tablets 5 Mg – Generic Inlyta within physician-directed kidney cancer management strategies.

Side Effects and Safety Profile

Most Common Side Effects:

• Diarrhea
• Skin rash or irritation
• Mouth sores (Stomatitis)
• Nail inflammation
• Eye irritation
• Nausea, loss of appetite

Serious Side Effects (Less Common but Critical):

• Interstitial lung disease
• Liver toxicity (elevated ALT/AST enzymes)
• Dehydration due to persistent diarrhea
• Heart arrhythmia
• Vision changes

Afatinib (like Gilotrif) requires regular monitoring of:

• Liver function
• Electrolyte levels
• ECG (heart rhythm)
• Skin and gastrointestinal health

Warning: Do NOT use Afatinib during pregnancy or breastfeeding. It can cause harm to the unborn baby. Effective contraception must be used during treatment and 2 weeks after the last dose.

Storage and Handling

• Store at room temperature: 20°C–25°C (68°F–77°F)
• Keep in original packaging
• Protect from direct sunlight, moisture, and heat
• Keep out of the reach of children and pets

Proper medication storage conditions and pharmaceutical stability guidance can also be referenced through patient drug information provided by MedlinePlus.

Manufacturing & Quality

• Produced in WHO-GMP and US FDA-compliant facilities
• Identical active molecule as Gilotrif (Afatinib Dimaleate)
• Tested for bioequivalence, purity, and potency
• Secure global shipping with regulated cold chain (where applicable)

  FAQ’s